Core Viewpoint - Heng Rui Medicine's subsidiary, Fujian Shengdi Pharmaceutical Co., Ltd., has received the acceptance notice from the National Medical Products Administration for the drug listing application of HRS9531 injection, indicating progress in the company's product pipeline and potential market entry for a new diabetes treatment [1] Company Summary - HRS9531 injection is a novel dual agonist targeting GLP-1R and GIPR, with global independent intellectual property rights [1] - The drug aims to regulate glucose and lipid metabolism, suppress appetite, and enhance insulin sensitivity, thereby improving blood sugar levels and aiding weight loss [1]